DIGITAL-ENVOY
Digital Envoy, the inventor of IP intelligence, today announced that Jerrod Stoller has been appointed as its new President. Current President and CEO Bill Calpin has stepped back from his role and has been named Chairman of the Board. Co-founder and Executive Vice President Rob Friedman assumes a dual role with the addition of the Vice-Chairman title.
Stoller will assume day-to-day leadership of Digital Envoy, overseeing operations for all three business units: Digital Element , Digital Resolve and Gathr Lab . His focus will be driving product innovation and market strategy across all three business units to align all offerings even closer with the needs of current customers and the marketplaces at large.
“The Digital Envoy team has accomplished great things since our start in 1999, and I am extremely proud of the growth and success our teams have achieved during that time,” said Calpin. “Our accomplishments have always been reliant on the entire team and the common goal of making Digital Envoy bigger and better. As Jerrod joins the team, all of us will continue to play key roles in helping our company maximise its potential. Based on his past experiences and successes, it’s easy to understand the enthusiasm our entire team has for Jerrod joining and leading our company into the future.”
Before joining Digital Envoy, Stoller was CEO of eVestment where he had directed the sales, marketing, client success and business development activities of the organisation globally for almost 10 years. He took on the CEO role 18 months ago, while retaining his other duties. Before joining eVestment, Stoller was the Regional Manager of RSA, the Security Division of EMC, where he directed company performance into triple-digit growth. Prior to RSA, he held leadership roles with Datalex Transportation Enterprise Software, Siemens Business Services, TransQuest Business Consulting and NCR. Stoller holds a bachelor’s degree in finance from Purdue University.
“I am thrilled to assume this new role and incredibly excited about what we can accomplish together for the future,” said Stoller. “There is tremendous opportunity ahead for Digital Envoy. I look forward to continuing to support our clients at the highest levels as well as innovating new market and product strategies within our industry niches to solve real-world problems.”
All changes are effective immediately.
“As Digital Envoy has continued to grow, we felt the need to expand the team to help focus on both the operational and strategic needs of the company,” said Friedman. “For Bill and I, our new roles provide opportunities to continue to stay engaged in the business while also providing us more time to address some of the longer-term opportunities and partnerships available to us as the markets continue to change.”
About Digital Envoy
Launched in 1999, Digital Envoy introduced the concept of privacy-sensitive IP-based geolocation and IP intelligence, allowing businesses—from ad networks to publishers to websites to retailers and more—to harness the power of location and new intelligence about connected users for a multitude of mission-critical applications. Taking more of a background role, in 2005 Digital Envoy introduced two divisions to help best address the unique needs of its diverse audience segments and business applications: Digital Element, which was created to continue the legacy of providing global geolocation data and services that bring anytime, anywhere relevance and context to online and mobile initiatives; and Digital Resolve, which was launched to deliver solutions that proactively secure online accounts, information, transactions and interactions from login to logout. In 2019, Digital Envoy launched Gathr Lab to further expand on its two decades of location data expertise and provide anonymous, custom audience insights and segments at scale, across all devices. By helping clients to reach, understand and amplify their best audiences, Gathr Lab is leading change by committing to data anonymity and refreshing transparency rooted in location-based data science. Visit www.digitalenvoy.com for more information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200714005066/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom